- Home
- HAYW vs ACLX Comparison
HAYW vs ACLX Comparison
Compare HAYW & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- ACLX
- Stock Information
- Founded
- HAYW 1925
- ACLX 2015
- Country
- HAYW United States
- ACLX United States
- Employees
- HAYW N/A
- ACLX N/A
- Industry
- HAYW Electronic Components
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- HAYW Technology
- ACLX Health Care
- Exchange
- HAYW Nasdaq
- ACLX Nasdaq
- Market Cap
- HAYW 3.5B
- ACLX 4.1B
- IPO Year
- HAYW 2021
- ACLX 2022
- Fundamental
- Price
- HAYW $15.12
- ACLX $76.42
- Analyst Decision
- HAYW Hold
- ACLX Strong Buy
- Analyst Count
- HAYW 5
- ACLX 13
- Target Price
- HAYW $17.33
- ACLX $114.75
- AVG Volume (30 Days)
- HAYW 2.0M
- ACLX 507.4K
- Earning Date
- HAYW 10-28-2025
- ACLX 11-06-2025
- Dividend Yield
- HAYW N/A
- ACLX N/A
- EPS Growth
- HAYW 46.31
- ACLX N/A
- EPS
- HAYW 0.60
- ACLX N/A
- Revenue
- HAYW $1,083,088,000.00
- ACLX $56,979,000.00
- Revenue This Year
- HAYW $5.74
- ACLX N/A
- Revenue Next Year
- HAYW $5.40
- ACLX $174.18
- P/E Ratio
- HAYW $25.26
- ACLX N/A
- Revenue Growth
- HAYW 8.77
- ACLX N/A
- 52 Week Low
- HAYW $11.10
- ACLX $47.86
- 52 Week High
- HAYW $16.87
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- HAYW 40.77
- ACLX 61.10
- Support Level
- HAYW $15.56
- ACLX $73.16
- Resistance Level
- HAYW $16.11
- ACLX $78.61
- Average True Range (ATR)
- HAYW 0.39
- ACLX 2.84
- MACD
- HAYW -0.13
- ACLX 0.55
- Stochastic Oscillator
- HAYW 3.72
- ACLX 75.42
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.